Evidence map›Paper›PMID 29099049›Full record

ArticleInternational journal of molecular sciences2017

Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.

Nalo Hamilton, David Austin, Diana Márquez-Garbán, Rudy Sanchez, Brittney Chau, Kay Foos, Yanyuan Wu, Jaydutt Vadgama, Richard Pietras

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Nalo HamiltonUCLA School of Nursing, University of California at Los Angeles, Los Angeles, CA 90095, USA. nhamilton@sonnet.ucla.edu.ORCID 0000-0002-6717-8079
David AustinDepartment of Medicine, Division of Cancer Research and Training, Charles Drew University School of Medicine and Science, Los Angeles, CA 90059, USA. davidaustin@cdrewu.edu.
Diana Márquez-GarbánUCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA 90095, USA. dmarquez@mednet.ucla.edu.
Rudy SanchezDepartment of Biology, California State University Channel Islands, Camarillo, CA 93012, USA. rudy.sanchez917@myci.csuci.edu.
Brittney ChauDepartment of Integrative Ecology and Evolutionary Biology and Physiology, UCLA College of Life Sciences, University of California at Los Angeles, Los Angeles, CA 90095, USA. chaubrittney@gmail.com.
Kay FoosDepartment Physiological, UCLA College of Life Sciences, University of California at Los Angeles, Los Angeles, CA 90095, USA. kaymaliafoos@yahoo.com.
Yanyuan WuDepartment of Medicine, Division of Cancer Research and Training, Charles Drew University School of Medicine and Science, Los Angeles, CA 90059, USA. yanyuanwu@cdrewu.edu.
Jaydutt VadgamaUCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA 90095, USA. jayvadgama@cdrewu.edu.
Richard PietrasDepartment of Medicine, Division of Cancer Research and Training, Charles Drew University School of Medicine and Science, Los Angeles, CA 90059, USA. rpietras@mednet.ucla.edu.
University of California, Los Angeles · USCharles R. Drew University of Medicine and Science · USCalifornia State University, Channel Islands · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Supporting African American Churches to Promote Cancer ScreeningU54CA143931 · NCI · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI VADGAMA, JAYDUTT V. · 2009 to 2022
$19.7M
Training and Mentoring ProgramsU54CA143930 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PIETRAS, RICHARD JOSEPH · 2009 to 2020
$7.5M
The Early Detection Research Network Biomarker Resource Laboratory at UCLAU24CA086366 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S. · 2000 to 2014
$7.3M
NCATS NIH HHS UL1 TR000124NCI NIH HHS U24 CA086366NCI NIH HHS U54 CA143930NCI NIH HHS U54 CA143931
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) occurs in 10-15% of all breast cancer patients, yet it accounts for about half of all breast cancer deaths. There is an urgent need to identify new antitumor targets to provide additional treatment options for patients afflicted with this aggressive disease. Preclinical evidence suggests a critical role for insulin-like growth factor-2 (IGF2) and androgen receptor (AR) in regulating TNBC progression. To advance this work, a panel of TNBC cell lines was investigated with all cell lines showing significant expression of IGF2. Treatment with IGF2 stimulated cell proliferation in vitro (

Indexed as

Androgen AntagonistsAndrogensAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesCell Line, TumorCell ProliferationCell SurvivalFemaleHumansInsulin-Like Growth Factor IIMolecular Targeted TherapyNitrilesPhenylthiohydantoinPyrazolesPyrimidinesAndrogen AntagonistsAndrogensAntineoplastic AgentsBenzamidesBMS 754807enzalutamideIGF2 protein, humanInsulin-Like Growth Factor IINitrilesNVP-AEW541PhenylthiohydantoinPyrazolesPyrimidinesPyrrolesReceptor, IGF Type 1TriazinesAKT kinaseandrogen receptorapoptosisBMS-754807enzalutamideIGF1R/IR inhibitionIGF2 signalinginsulin-like growth factor-2NVP-AEW541triple-negative breast cancer

Identifiers

PMID29099049
PMCPMC5713274
OpenAlexW2765923361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.